Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment

[1]  A. Arcaro.  Targeted therapies for small cell lung cancer: Where do we stand? , 2015, Critical reviews in oncology/hematology.

[2]  A. Motta,et al.  Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach. , 2015, Cancer research.

[3]  P. Nelson,et al.  Integrative molecular profiling of routine clinical prostate cancer specimens. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[5]  A. Hartmann,et al.  Frequency of TERT Promoter Mutations in Prostate Cancer , 2015, Pathobiology.

[6]  S. Tomlins,et al.  Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma , 2015, Virchows Archiv.

[7]  P. Vlachostergios,et al.  Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives , 2015, Front. Oncol..

[8]  J. Fallon,et al.  Distinct genetic alterations in small cell carcinoma from different anatomic sites , 2015, Experimental Hematology & Oncology.

[9]  V. Subbiah,et al.  Exceptional responders: in search of the science behind the miracle cancer cures. , 2015, Future oncology.

[10]  W. Lu,et al.  Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma , 2014, Journal of Hematology & Oncology.

[11]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[12]  Shanghai Yu,et al.  SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. , 2014, Cancer research.

[13]  T. Yap,et al.  Strategies for modern biomarker and drug development in oncology , 2014, Journal of Hematology & Oncology.

[14]  Ximing J. Yang,et al.  High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins , 2014, Journal of Hematology & Oncology.

[15]  R. Bergan,et al.  Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis , 2014, PloS one.

[16]  N. Socci,et al.  Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. , 2014, Cancer discovery.

[17]  M. Ladanyi,et al.  Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  H. Beltran,et al.  The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression , 2014, Front. Oncol..

[19]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[20]  M. Nieto.  Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells , 2013, Science.

[21]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[22]  A. R. Brannon,et al.  "N of 1" case reports in the era of whole-genome sequencing. , 2013, The Journal of clinical investigation.

[23]  H. Beltran,et al.  Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. , 2013, Neoplasia.

[24]  K. Welén,et al.  Midkine is associated with neuroendocrine differentiation in castration‐resistant prostate cancer , 2013, The Prostate.

[25]  M. Saha,et al.  Targeting p53 by small molecules in hematological malignancies , 2013, Journal of Hematology & Oncology.

[26]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[27]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[28]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[29]  Robert H. Bell,et al.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer , 2012, The Journal of pathology.

[30]  C. Liang,et al.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. , 2012, Endocrine-related cancer.

[31]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[32]  J. Donovan,et al.  Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population‐based study , 2012, BJU international.

[33]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[34]  R. Montironi,et al.  ERG–TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin , 2011, Modern Pathology.

[35]  V. Rotter,et al.  TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model , 2011, PloS one.

[36]  C. Bieberich,et al.  ERG gene rearrangements are common in prostatic small cell carcinomas , 2011, Modern Pathology.

[37]  Laurence Doyle,et al.  Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures , 2011, PloS one.

[38]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[39]  R. Shah,et al.  Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma , 2009, Modern Pathology.

[40]  C. Bieberich,et al.  Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate , 2009, The Prostate.

[41]  J. Donovan,et al.  SURVIVAL OF PATIENTS WITH SMALL CELL CARCINOMA OF THE PROSTATE DURING 1973-2003: A POPULATION BASED STUDY , 2009 .

[42]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[43]  M. Yashi,et al.  Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review. , 2006, Urologic oncology.

[44]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[45]  C. Hill,et al.  Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. , 2004, The Biochemical journal.

[46]  C. Hill,et al.  Loss of Smad4 Function in Pancreatic Tumors , 2001, The Journal of Biological Chemistry.

[47]  J. Shimazaki,et al.  Progression of prostate cancer to neuroendocrine cell tumor , 2001, International journal of urology : official journal of the Japanese Urological Association.

[48]  Ximing J. Yang,et al.  Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. , 2001, Cancer research.

[49]  W. Stadler,et al.  Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. , 1999, Cancer research.

[50]  Stephen Moore,et al.  Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. , 2015, The Journal of molecular diagnostics : JMD.